Kathy Oubre Previews Festival of Biologics 2022 Discussions

Kathy Oubre, MS, chief operating officer of Pontchartrain Cancer Center, previews her upcoming presentations at the Festival of Biologics conference.

Transcript

You are going to be speaking at Terrapinn’s Festival of Biologics conference happening in March. What are you going to be discussing and what can audiences look forward to?

I will be doing a panel presentation with Sean McGowan [AmerisourceBergen]; Bhavesh Shah, RPh, BCOP; and Craig [Burton] from AAM [Association for Accessible Medicines]. We're doing the keynote on the first day, and we'll be discussing present and future considerations for the biosimilar industry. We're going to be doing a much broader kind of a 30,000-foot discussion, and in that, will talk about the current biosimilars market products and some industry milestones: where we started, where we are now, and we are going to be looking forward. We will discuss what we see coming as far as launches and what's going to be happening in the space within the next 6 months, the next year, the next 5 years. And then we'll be having probably a fairly robust discussion regarding the regulatory constraints and some policy implications around biosimilars.

Additionally, on the third day, I will be doing a panel presentation with Melody Chang, RPh, MBA, BCOP, at AON [American Oncology Network] and we'll be discussing the importance of biosimilars within the oncology landscape and kind of a crystal ball discussion of where we see biosimilars in oncology moving forward.